STRO Stock Overview
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.
Sutro Biopharma, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.10|
|52 Week High||US$16.60|
|52 Week Low||US$3.33|
|1 Month Change||-3.66%|
|3 Month Change||23.26%|
|1 Year Change||-54.37%|
|3 Year Change||-29.77%|
|5 Year Change||n/a|
|Change since IPO||-53.29%|
Recent News & Updates
New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)Aug 11
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?May 02
Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?Dec 26
Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue ForecastsMay 09
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?May 07
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?Jan 06
|STRO||US Biotechs||US Market|
Return vs Industry: STRO underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: STRO underperformed the US Market which returned -14.9% over the past year.
|STRO Average Weekly Movement||8.0%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: STRO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: STRO's weekly volatility (8%) has been stable over the past year.
About the Company
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+ The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.
Sutro Biopharma, Inc. Fundamentals Summary
|STRO fundamental statistics|
Is STRO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STRO income statement (TTM)|
|Cost of Revenue||US$123.96m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.14|
|Net Profit Margin||-175.85%|
How did STRO perform over the long term?See historical performance and comparison